Cargando…

HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1

Therapy of acute myeloid leukemia (AML) is unsatisfactory. Histone deacetylase inhibitors (HDACi) are active against leukemic cells in vitro and in vivo. Clinical data suggest further testing of such epigenetic drugs and to identify mechanisms and markers for their efficacy. Primary and permanent AM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beyer, Mandy, Romanski, Annette, Mustafa, Al-Hassan M., Pons, Miriam, Büchler, Iris, Vogel, Anja, Pautz, Andrea, Sellmer, Andreas, Schneider, Günter, Bug, Gesine, Krämer, Oliver H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826998/ https://www.ncbi.nlm.nih.gov/pubmed/31561534 http://dx.doi.org/10.3390/cancers11101436

Ejemplares similares

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021)

Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors
por: Zhang, Zhihua, et al.
Publicado: (2013)

β-catenin and γ-catenin are dispensable for T lymphocytes and AML leukemic stem cells
por: Zhao, Xin, et al.
Publicado: (2020)

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2017)

Regulation of retinoic acid synthetic enzymes by WT1 and HDAC inhibitors in 293 cells
por: Li, Yifan, et al.
Publicado: (2017)

Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability
por: Ma, Zhi-Qiang, et al.
Publicado: (2022)

EFFECT OF THAI SARAPHI FLOWER EXTRACTS ON WT1 AND BCR/ABL PROTEIN EXPRESSION IN LEUKEMIC CELL LINES
por: Sangkaruk, Rungkarn, et al.
Publicado: (2017)

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

HDAC6 inhibitor WT161 induces apoptosis in retinoblastoma cells and synergistically interacts with cisplatin
por: Sun, Jun, et al.
Publicado: (2019)

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
por: Zeyn, Yanira, et al.
Publicado: (2023)

β-catenin induces expression of prohibitin gene in acute leukemic cells
por: Kim, Dong Min, et al.
Publicado: (2017)

TERT Expression in Wilms Tumor Is Regulated by Promoter Mutation or Hypermethylation, WT1, and N-MYC
por: Jablonowski, Carolyn M., et al.
Publicado: (2022)

HDAC1 and HDAC2 Regulate Oligodendrocyte Differentiation By Disrupting β-Catenin-TCF Interaction
por: Ye, Feng, et al.
Publicado: (2009)

The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells
por: Nilsson, Helena Jernmark, et al.
Publicado: (2017)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU
por: Sun, Jun, et al.
Publicado: (2021)

The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops
por: Ottema, Sophie, et al.
Publicado: (2021)

Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation
por: Lu, Yukai, et al.
Publicado: (2023)

HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130
por: Göder, Anja, et al.
Publicado: (2018)

Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells
por: Gao, Shen-meng, et al.
Publicado: (2012)

The DAC system and associations with acute leukemias and myelodysplastic syndromes
por: Bug, Gesine, et al.
Publicado: (2010)

miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level
por: Gao, Shen-meng, et al.
Publicado: (2011)

MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge
por: Bilgin, Yavuz Memis, et al.
Publicado: (2021)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells
por: Zhang, Yimeng, et al.
Publicado: (2023)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
por: Ibrahim, Hany S., et al.
Publicado: (2021)

EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism
por: Ramamoorthy, Senthilkumar, et al.
Publicado: (2020)

Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity
por: Fitzel, Rahel, et al.
Publicado: (2023)

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition
por: Tsai, Cheng-Yu, et al.
Publicado: (2021)

The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells
por: Bhandari, Dilli Ram, et al.
Publicado: (2011)

The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma
por: Barneda-Zahonero, B, et al.
Publicado: (2015)

Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities
por: Ota, Sara, et al.
Publicado: (2017)

miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth
por: Prashad, Nagindra
Publicado: (2018)

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
por: Wang, Qun, et al.
Publicado: (2016)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat
por: Chen, Jasmine, et al.
Publicado: (2023)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023)

WT1 β’ing catenin into shape: a new interaction driving epigenetic plasticity in acute myeloid leukemia?
por: Grey, William
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_upunn7dg2p861qofqu5g46ndk6